Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Sebti

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Archives of Biochemistry and Biophysics|February 15, 1996
Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblastsX Q Xu, T F McGuire, M A Blaskovich, et al.
The Journal of Biological Chemistry|March 6, 1999
The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activityJ Sun, Y Qian, Z Chen, et al.
Neurosurgery|July 10, 1998
Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growthM Bredel, I F Pollack, J M Freund, et al.
Oncology Research|January 1, 1992
In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64J P Jani, J S Mistry, G Morris, et al.
Cancer Research|January 1, 1991
Metabolic inactivation: a mechanism of human tumor resistance to bleomycinS M Sebti, J P Jani, J S Mistry, et al.
Biochemistry|August 8, 1989
Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase familyS M Sebti, J E Mignano, J P Jani, et al.
Biochemical and Biophysical Research Communications|October 14, 1994
Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activityT F McGuire, X Q Xu, S J Corey, et al.
Cell Death and Differentiation|June 12, 2002
The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation statusN C Crespo, F Delarue, J Ohkanda, et al.
Biochemical Pharmacology|January 1, 1989
Substrate specificity of bleomycin hydrolaseS M Sebti, J C DeLeon, L T Ma, et al.
Biochemistry|September 26, 1995
Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different divalent cation requirementsA Vogt, J Sun, Y Qian, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Archives of Biochemistry and Biophysics|February 15, 1996
Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblastsX Q Xu, T F McGuire, M A Blaskovich, et al.
The Journal of Biological Chemistry|March 6, 1999
The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activityJ Sun, Y Qian, Z Chen, et al.
Neurosurgery|July 10, 1998
Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growthM Bredel, I F Pollack, J M Freund, et al.
Oncology Research|January 1, 1992
In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64J P Jani, J S Mistry, G Morris, et al.
Cancer Research|January 1, 1991
Metabolic inactivation: a mechanism of human tumor resistance to bleomycinS M Sebti, J P Jani, J S Mistry, et al.
Biochemistry|August 8, 1989
Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase familyS M Sebti, J E Mignano, J P Jani, et al.
Biochemical and Biophysical Research Communications|October 14, 1994
Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activityT F McGuire, X Q Xu, S J Corey, et al.
Cell Death and Differentiation|June 12, 2002
The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation statusN C Crespo, F Delarue, J Ohkanda, et al.
Biochemical Pharmacology|January 1, 1989
Substrate specificity of bleomycin hydrolaseS M Sebti, J C DeLeon, L T Ma, et al.
Biochemistry|September 26, 1995
Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different divalent cation requirementsA Vogt, J Sun, Y Qian, et al.
Pageof 11